Cat. No.: HY-B0135

Furosemide

9 Cited Publications

Customer Review

Based on 9 publication(s) in Google Scholar

Furosemide is a potent and orally active inhibitor of Na⁺/K⁺/2Cl^- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide is also a GABA_A receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.

For research use only. We do not sell to patients.

Purity: 99.83%
CAS No.: 54-31-9
Formula: C₁₂H₁₁ClN₂O₅S
Molecular Weight:330.74

Storage:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Furosemide Chemical Structure

CAS No.: 54-31-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (9)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Furosemide is a potent and orally active inhibitor of Na⁺/K⁺/2Cl^- (NKCC) cotransporter, NKCC1 and NKCC2^[1]. Furosemide is also a GABA_A receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema^[2].

IC₅₀ & Target

IC50: NKCC1 and NKCC2^[1]
IC50: GABA_A receptors^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	11.2 μM Compound: 7	Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay	[PMID: 23888932]
HEK293	IC₅₀	3.76 μM Compound: 2	Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH	[PMID: 18653260]
HEK293	IC₅₀	3.76 μM Compound: 2	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay in presence of NADPH	[PMID: 18653260]
HEK293	IC₅₀	>500 μM Compound: furosemide	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HeLa	IC₅₀	15 μM Compound: Furosemide	TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells	[PMID: 10565843]
Sf21	IC₅₀	>1000 μM Compound: Furosemide	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	>1000 μM Compound: Furosemide	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

In Vitro

Furosemide (500 μM; 72-96 hours) significantly changes the proliferation rates in MKN45 cells (the poorly differentiated human gastric adenocarcinoma cell line). however, it has no effects on MKN28 cells (the moderately differentiated human gastric adenocarcinoma cell line). The growth rate of MKN45 cells is larger than that of MKN28 cells^[4].
Furosemide (10 μM, 30 μM, 100 μM; 45 min exposure) significantly decreases cation channel activity and [Ca(2+)](i) in human erythrocytes drawn from healthy individuals. Tert-butylhydroperoxide similarly enhances the non-selective cation channels activity, increases [Ca(2+)](i) and triggered cell membrane scrambling, however, the effects is significantly blunted by furosemide again^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Furosemide (intraperitoneal injection; 100 mg/kg; single dose) is injected after kanamycin (KM) (1000 mg/kg) to creat a deaf mouse model in C57BL/6 mouse. After injection, hearing loss and cochlear hair cell damage are evaluated on day 1, day 2 and day 3, respectively. The hearing is markedly deteriorated even from the next day (Day-1 group), OHCs (outer hair cell) morphology of apical, middle and basal turns are disorganized in mice on day3^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 54-31-9
Appearance Solid
Molecular Weight 330.74
Formula C₁₂H₁₁ClN₂O₅S
Color White to off-white
SMILES

O=C(O)C1=CC(S(=O)(N)=O)=C(Cl)C=C1NCC2=CC=CO2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (9)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayELISAIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

Nat Aging

mRNA metabolism regulator human antigen R (HuR) regulates age-related hearing loss in aged mice. [Abstract]

2025 May;5(5):848-867. PMID: 40394214
Sci Adv

3D bioprinted human-scale intestine models for physiological and microbial insights through fluid-driven heterogeneity. [Abstract]

2025 Nov 21;11(47):eady6562. PMID: 41270182
EMBO J

Structural basis for human NKCC1 inhibition by loop diuretic drugs. [Abstract]

2025 Mar;44(5):1540-1562. PMID: 39875725
Emerg Contam

2026 Feb 23.
Eur J Pharmacol

Loop diuretics mitigate juvenile immobilization treatment-induced hippocampal dysfunction. [Abstract]

2025 Jun 5:996:177447. PMID: 40023355

Furosemide purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Jun 5:996:177447. [Abstract]

Suprafusion of bumetanide and Furosemide (50 μM ; 65 min) inhibited LTP formation in the hippocampus, with typical traces in the right panels. Points a and b represent high-frequency stimulation (HFS) for 5 min before induction and 40 min after induction, respectively.

Furosemide purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Jun 5:996:177447. [Abstract]

At the 40-min time point (b), hippocampal LTP was measured with suprafusion of 5 μM bumetanide or 50 μM Furosemide.

Furosemide purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Jun 5:996:177447. [Abstract]

In the inhibitory avoidance test, each group received intraperitoneal injections of either a vehicle, 15.2 mg/kg bumetanide, or 152 mg/kg Furosemide (dissolved in 1.1% DMSO in PBS) 30 min prior to the extinction phase (n = 9 per group).
iScience

Heart failure pleural fluid impairs endothelial barrier through miR 501-3p mediated ZO 1 remodeling. [Abstract]

2026 Apr 2;29(5):115549. PMID: 42058897
iScience

Impact of endogenous sonosensation on in vivo sonogenetics. [Abstract]

2025 Nov 12;28(12):114030. PMID: 41377656
J Pharm Biomed Anal

Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]

2021 Feb 20:195:113870. PMID: 33453569
J Orthop Surg Res

Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy. [Abstract]

2024 Feb 19;19(1):147. PMID: 38373964

Furosemide purchased from MedChemExpress. Usage Cited in: J Orthop Surg Res. 2024 Feb 19;19(1):147. [Abstract]

Furosemide (10 μM; 1-6 days) had no effect on MCA-205 growth. CCK8 experiment was used to detect the proliferation ability of MCA-205 after Furosemide treatment.

Furosemide purchased from MedChemExpress. Usage Cited in: J Orthop Surg Res. 2024 Feb 19;19(1):147. [Abstract]

Furosemide (10 μM; 24 h) did not significantly alter the level of VEGF produced by MCA-205. Elisa kit was used to detect the VEGF production after furosemide treatment.

Furosemide purchased from MedChemExpress. Usage Cited in: J Orthop Surg Res. 2024 Feb 19;19(1):147. [Abstract]

Furosemide (200 mg/kg; ip; every other day) did not inhibit MCA-205 fibrosarcoma growth.

Furosemide purchased from MedChemExpress. Usage Cited in: J Orthop Surg Res. 2024 Feb 19;19(1):147. [Abstract]

Furosemide (200 mg/kg; ip; every other day) combination of PD1ab (250 µg/mice; ip; every other day, 4 times) displayed a weaker therapeutic impact on tumor growth when compared with PD1ab single therapy.

Furosemide purchased from MedChemExpress. Usage Cited in: J Orthop Surg Res. 2024 Feb 19;19(1):147. [Abstract]

Furosemide (200 mg/kg; ip; every other day) combination with PD1ab (250 µg/mice; ip; every other day, 4 times) showed no impact on the level of infiltrating CD8+ T cells compared with control. Compared with PD1ab treatment alone, the combination of both agents showed a decreasing impact on the level of infiltrating CD8+ T cells.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (302.35 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0235 mL

15.1176 mL

30.2352 mL

5 mM

0.6047 mL

3.0235 mL

6.0470 mL

10 mM

0.3024 mL

1.5118 mL

3.0235 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. C M Gillen, et al. Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human. A new member of the cation-chloride cotransporter family. J Biol Chem. 1996 Jul 5;271(27):16237-44. [Content Brief]

[2]. S A Thompson, et al. Residues in transmembrane domains I and II determine gamma-aminobutyric acid type AA receptor subtype-selective antagonism by Furosemide sodium. Mol Pharmacol. 1999 Jun;55(6):993-9. [Content Brief]

[3]. Shin Hye Kim, et al. Novel Peptide Vaccine GV1001 Rescues Hearing in Kanamycin/Furosemide sodium-Treated Mice. Front Cell Neurosci. 2018 Jan 19;12:3. [Content Brief]

[4]. Atsushi Shiozaki , et al. Furosemide sodium, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state. J Physiol Sci. 2006 Dec;56(6):401-6. [Content Brief]

[5]. Yuliya V Kucherenko, et al.Inhibitory effect of Furosemide sodium on non-selective voltage-independent cation channels in human erythrocytes.Cell Physiol Biochem. 2012;30(4):863-75. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0235 mL	15.1176 mL	30.2352 mL	75.5881 mL
	5 mM	0.6047 mL	3.0235 mL	6.0470 mL	15.1176 mL
	10 mM	0.3024 mL	1.5118 mL	3.0235 mL	7.5588 mL
	15 mM	0.2016 mL	1.0078 mL	2.0157 mL	5.0392 mL
	20 mM	0.1512 mL	0.7559 mL	1.5118 mL	3.7794 mL
	25 mM	0.1209 mL	0.6047 mL	1.2094 mL	3.0235 mL
	30 mM	0.1008 mL	0.5039 mL	1.0078 mL	2.5196 mL
	40 mM	0.0756 mL	0.3779 mL	0.7559 mL	1.8897 mL
	50 mM	0.0605 mL	0.3024 mL	0.6047 mL	1.5118 mL
	60 mM	0.0504 mL	0.2520 mL	0.5039 mL	1.2598 mL
	80 mM	0.0378 mL	0.1890 mL	0.3779 mL	0.9449 mL
	100 mM	0.0302 mL	0.1512 mL	0.3024 mL	0.7559 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Furosemide

Anti-Infection Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Peptidomimetic Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

GABA Receptor Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Ion Channel Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Animal Drug Library

Nephrotoxicity Compound Library

Publications Citing Use of MedChemExpress (MCE) Furosemide

Biological Activity

Chemical Information

Publications (9)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Furosemide Related Classifications

Cat. No.: HY-B0135